

Serum/plasma PFAS levels

In this guide

[In this guide](#)

1. [Introduction, Background and Literature Search - PFAS/2023/06](#)
2. [In vivo liver toxicity studies - PFAS/2023/06](#)
3. [Endpoints Investigated and Summary of Results - PFAS/2023/06](#)
4. [Liver Weight - PFAS/2023/06](#)
5. [Clinical chemistry- PFAS/2023/06](#)
6. [Liver histopathology - PFAS/2023/06](#)
7. [Effects on gene expression - PFAS/2023/06](#)
8. [Serum/plasma PFAS levels - PFAS/2023/06](#)
9. [Discussion - PFAS/2023/06](#)
10. [Table 1 Lowest POD for PFAS based on liver effects - PFCAs](#)
11. [Table 2 Lowest POD for PFAS based on liver effects - PFSA](#)s
12. [Questions on which the views of the Committee are sought - PFAS/2023/06](#)
13. [List of Abbreviations - PFAS/2023/06](#)
14. [References - PFAS/2023/06](#)

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

178. Levels of PFCAs in serum or plasma were measured in 11 repeated dose studies and in one developmental study and levels of PFSA were measured in 13 repeated dose studies.

179. Levels of PFCAs and PFSA in males were typically higher than their female counterparts at the same dose levels, suggesting a sex-specific difference in plasma concentrations for certain PFAS and that males and females respond differently to exposure. These results will be evaluated further in subsequent papers considering the toxicokinetics of PFAS.